Skip to main content
Erschienen in: Cardiovascular Intervention and Therapeutics 4/2022

21.02.2022 | Images in Cardiovascular Intervention

Avoidance strategy for coronary obstruction in patient with anomalous origin of the left circumflex undergoing transcatheter aortic valve implantation

verfasst von: Naoto Setoguchi, Masahiko Asami, Jun Tanaka, Motoi Yokozuka, Sumio Miura, Kengo Tanabe

Erschienen in: Cardiovascular Intervention and Therapeutics | Ausgabe 4/2022

Einloggen, um Zugang zu erhalten

Excerpt

A 76-year-old woman with a history of stroke with severe hemiplegia was hospitalized for decompensated heart failure due to severe aortic stenosis (The Society of Thoracic Surgeons scores of predicted risk of mortality 4.05 points). The local heart-team decided to perform a transcatheter aortic valve implantation (TAVI) instead of surgical aortic valve replacement (SVAR) in view of her poor mobility (Clinical Frailty Scale; 7) caused by hemiplegia which might not be able to rehabilitate enough after the procedure. Pre-procedural computed tomography (CT) scans revealed an anomalous origin of the left circumflex coronary artery (LCX) from the right coronary cusp below the ostium of the right coronary artery, running through between the aortic valve apparatus and right atrium (Fig. 1A, B). Coronary heights at the RCA, LAD, and LCX were 12.60, 14.20, and 12.60 mm, respectively. In the local heart-team discussion, we had concerned that coronary obstruction at the mid-portion of LCX between aortic valve complex and pulmonary artery might be caused by mechanical compression of pre-dilatation or THV implantation. However, we had not expected for coronary occlusion at the ostium of coronary arteries because coronary heights were enough high to implant THV safely. Therefore, we determine to perform coronary protection if pre-dilatation led to coronary obstruction. During TAVI, the LCX was transiently occluded (Fig. 1C, D) after full inflation of a 20-mm balloon (Tokai Medical, Aichi, Japan) for pre-dilatation. A 0.014-inch guidewire and a 2.5 × 15 mm semi-compliant balloon (SAPPHIRE3; OrbusNeich, Wanchai, Hong Kong) were delivered to the LCX for coronary protection. Pre-procedural CT scans (area 341.1 mm2, perimeter 68.0 mm) recommended a 23-mm SAPIEN3 valve (Edwards Lifesciences, Irvine, California); however, a 20-mm SAPIEN3 valve was selected based on previous literature that showed coronary obstruction using the recommended 23-mm transcatheter heart valve (THV) [1]. The LCX had 75% stenosis during full inflation of the balloon for THV expansion (Fig. 1E, F). Mild paravalvular leakage was detected; therefore, post-dilatation was performed by inflating the THV balloon with 1 mL more. Since there was no change in coronary stenosis despite deflating the balloon for BAV, intracoronary nitrate was administrated due to the suspicion of a vasospasm caused by mechanical compression of the THV. Subsequently, the LCX expanded without remaining stenosis (Fig. 1G). An intravascular ultrasound revealed no organic lesion (Fig. 1H–L); therefore, a vasospasm may have caused the LCX stenosis. In a TAVI procedure, the coronary artery with anomalous origin is at high-risk for coronary obstruction; however, the combination of a one-size-smaller THV and the intracoronary administration of nitrate may reduce this risk and avoid inappropriate coronary stenting.
Literatur
1.
Zurück zum Zitat Acosta-Vélez JG, del Blanco GB, Guindo J, et al. Acute artery occlusion during transcatheter aortic valve replacement in a patient with an anomalous origin of the circumflex artery. JACC Cardiovasc Interv. 2014;7:1324–5.CrossRef Acosta-Vélez JG, del Blanco GB, Guindo J, et al. Acute artery occlusion during transcatheter aortic valve replacement in a patient with an anomalous origin of the circumflex artery. JACC Cardiovasc Interv. 2014;7:1324–5.CrossRef
Metadaten
Titel
Avoidance strategy for coronary obstruction in patient with anomalous origin of the left circumflex undergoing transcatheter aortic valve implantation
verfasst von
Naoto Setoguchi
Masahiko Asami
Jun Tanaka
Motoi Yokozuka
Sumio Miura
Kengo Tanabe
Publikationsdatum
21.02.2022
Verlag
Springer Nature Singapore
Erschienen in
Cardiovascular Intervention and Therapeutics / Ausgabe 4/2022
Print ISSN: 1868-4300
Elektronische ISSN: 1868-4297
DOI
https://doi.org/10.1007/s12928-022-00848-0

Weitere Artikel der Ausgabe 4/2022

Cardiovascular Intervention and Therapeutics 4/2022 Zur Ausgabe

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.